drugset / Trial / NCT01738347
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
Phase 1
Completed
30 enrolled
GE Healthcare
Centre for Probe Development and Commercialization · collab
NaSingle-groupOpen-labelOther
Summary
To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the Imaging Protocol of GEH120714 (18F) Injection. Study recruits healthy volunteers and participants with relapsing and remitting multiple sclerosis.
Timeline
- Start
- 2013-04
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GEH120714 | Unknown | 100 mbq | Intravenous |
| Subject | GEH120714 | Unknown | 270 mbq | Intravenous |